Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Kidney drug study aims to understand Body's processing, not cure

NCT ID NCT07348237

First seen Jan 17, 2026 · Last updated May 23, 2026 · Updated 13 times

Summary

This early-stage study looks at how the drug MK-2828 behaves in people with different levels of kidney function, including those with severe kidney failure or on dialysis. About 24 adults will receive one or two doses, and researchers will measure drug levels in the blood over time. The goal is purely to gather information—there is no treatment or cure involved.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Floridian Clinical Research ( Site 0001)

    RECRUITING

    Miami Lakes, Florida, 33016, United States

    Contact Phone: •••-•••-••••

  • Orlando Clinical Research Center ( Site 0002)

    RECRUITING

    Orlando, Florida, 32809, United States

    Contact Phone: •••-•••-••••

  • Panax Clinical Research ( Site 0003)

    RECRUITING

    Miami Lakes, Florida, 33014, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.